Skip to main content
main-content

15-06-2022 | ASCO 2022 | Conference coverage | Video

Reflections on the DESTINY-Breast04 trial

share
SHARE

Patricia LoRusso provides an independent comment on the DESTINY-Breast04 trial showing the benefit of trastuzumab deruxtecan for people with HER2-low metastatic breast cancer, and discusses the challenges involved (5:02).

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

2022 ASCO Annual Meeting coverage

Access the latest news and expert insight from the 2022 ASCO Annual Meeting